in cervical cancer immunotherapy at major international conferences
Time of Update: 2022-09-21
The results of multiple subgroup analyses of the Keynote826 study were published at the 2022 ASCO Annual Meeting, which showed that pembolizumab plus chemotherapy (paclitaxel + cisplatin/carboplatin) ± bevacizumab for first-line treatment of relapsed or metastatic cervical cancer, significantly improved progression-free survival (PFS: 10.
2022 ESMO:DZD1516 International Multicenter Breast Cancer Clinical Study Results Positive
Time of Update: 2022-09-14
Based on the unique tumor central nervous system metastasis research platform, Di Zhe designed and developed DZD1516, a highly selective HER2 inhibitor with the ability to fully penetrate the blood-brain barrier.
Scientists are expected to use nutritional supplements to shrink breast cancer tumors (2022 Beijing International Life and Health Expo)
Time of Update: 2022-09-08
com]Responsible Editor: Original: Scientists are expected to use nutritional supplements to shrink breast cancer tumors (2022 Beijing International Life and Health Expo)According to data released by the WHO International Agency for Research on Cancer, the number of new cases of breast cancer worldwide is as high as 2.
【Chinese Achievements】Professor Shen Lin from Beijing Cancer Hospital leads the International
Time of Update: 2022-06-04
NEJM: Results from the AGILE trial confirm significant improvement in ivonib plus azacitidine compared with placebo plus azacitidine in patients with newly diagnosed IDH1-mutant acute myeloid leukemia who are ineligible for induction chemotherapy Event-free survival, remission and overall survival .
Monotherapy in China Phase I Clinical Trial at the 2022 International Gastric Cancer Congress
Time of Update: 2022-04-30
SUZHOU, March 10, 2022 /PRNewswire/ -- Chuangsheng Group, a clinical-stage biopharmaceutical company with the ability to integrate the whole process of biopharmaceutical discovery, R&D, process development and production, announced that at the 2022 International Gastric Cancer Congress (IGCC) ) in the form of a poster to show the safety, tolerability and preliminary efficacy data of TST001 monotherapy in the Phase I clinical trial in China and its antitumor activity against gastric and pancreatic cancer .
Meta-analysis of more than 130,000 people: This super-commonly used drug in internal medicine, used
Time of Update: 2022-04-17
Figure 3 Figure 3 In the trial subgroup without ace inhibitor treatment in both study arms, a statistically significant increase in cancer incidence was again seen only when the cumulative exposure time was >3 years Figure 3The meta-regression analysis shown in Figure 4, Panel A, examined the second co-primary outcome of cumulative exposure to ARBs and lung cancer risk .
J INTERN MED: Risk of primary liver cancer in patients with acute hepatic porphyria
Time of Update: 2022-03-03
In this registry-based, matched cohort study, researchers assessed associations with biochemical and clinical porphyria severity, genotype, age, and gender, according to a study published in the Journal of Internal Medicine.
Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1,244 individuals .
Innovate Group will announce the progress of two TST001 clinical trials at ASCO GI and IGCC International Gastric Cancer Conference
Time of Update: 2022-01-22
HK), a clinical-stage biopharmaceutical company with the ability to integrate the whole process of biological drug discovery, research and development, process development and production, announced that the US Phase I clinical trial of TST001 will be held on January 20-22, 2022 Presented as a Trial in Progress (TiP) poster at the American Society of Clinical Oncology Symposium on Gastrointestinal Oncology (ASCO GI) in San Francisco .
For the first-line treatment of small cell lung cancer, the international multi-center phase III
Time of Update: 2021-12-30
HK) announced that the company’s self-developed innovative PD-1 inhibitor slulimumab combined with chemotherapy is in A randomized, double-blind, international multi-center phase III clinical study (NCT04063163) of a previously untreated extensive-stage small cell lung cancer ( ES-SCLC ) has achieved overall survival ( OS ) in the first interim analysis The end .
2021 International Conference on Cancer and Aging and the Fifth Doctoral Forum
Time of Update: 2021-12-24
Chinese Chairman Liu Jianfeng, Professor of Huazhong University of Science and Technology, French Chairman, Prevost Gregoire, President of CIPREVO, France, and Professor Sylvain Fisson, representative of Évry University in France, then welcomed the experts, scholars and students participating in the conference and kicked off the conference .
Professor Lu Ming: Sofantinib combined with teriprizumab in the treatment of neuroendocrine cancer
Time of Update: 2021-12-06
The recent 2021 North American Society of Neuroendocrine Oncology (NANETS) annual meeting announced the latest data from the Phase II clinical study of sofatinib combined with teriprizumab in the treatment of advanced neuroendocrine cancer that failed first-line chemotherapy .
Home-made cervical cancer vaccine won the international "passport"
Time of Update: 2021-12-05
Breaking through the "99% bottleneck"-the domestic cervical cancer vaccine won the international "pass" October 14, 2021 is a memorable day, by the Xiamen University Xia Ningshao team and Yangshengtang Wantai Biotech's Xiamen The first domestic cervical cancer vaccine "Xinkening" jointly developed by Wantai Canghai Biotechnology Co.
ATA International Conference: Thyroid-related "radioiodine therapy" may cause cancer concerns
Time of Update: 2021-11-16
Introduction: A research report published at the annual meeting of the American Thyroid Association in 2021 showed that compared with young people who did not receive radioactive iodine therapy (RAI), young people who received RAI had a 92% increase in the risk of leukemia and solid malignant tumors.
the therapeutic window of antibody-conjugated drugs (ADC) at the 33rd International Conference on Molecular Targets and Cancer Therapy
Time of Update: 2021-11-05
Based on the innovative technology platform, Pufang Bio has developed a series of product pipelines composed of drug candidates targeting solid tumor targets.
Drug Y officially landed in Jiahui International Cancer Center and became a pioneer in the use of dual immunotherapy in China
Time of Update: 2021-10-21
Shanghai, October 12, 2021/PRNewswire/ - On June 10, 2021, the first CTLA-4 inhibitor ipilimumab in China was approved by the China National Medical Products Administration (NMPA) to join Navuriu Mono